Pipeline And Commercial Insight: Alzheimers Disease - Market Cautiously Awaits The First Generation

Introduction

Introduction

Current management of Alzheimers disease is wholly inadequate, providing only symptomatic benefit to patients in whom the underlying neurodegeneration continues unabated. However, with the launch of the first disease-modifying drugs, combined with the availability of predictive biomarker tests that enable earlier diagnosis, the Alzheimers disease treatment paradigm is set to change radically.

Features and benefits

Forecasts of Alzheimers disease patient population numbers based on a comprehensive epidemiology review.

Breakdown of historic (2005-09) and future (2010-19) prescription sales across the seven major markets consisting of the US, Japan, and 5EU.

Review of the Alzheimers disease drug pipeline dynamics, including detailed profiles of key late-stage products.

Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.

Analysis of current treatment approaches, patient acquisition and clinical unmet needs.

Highlights

The value of the Alzheimers disease market across the seven major markets was $4.7bn in 2009 and is forecast to reach $11.9bn by 2019. Future market growth is set to be driven by the first disease-modifying drugs, given their significant price premium, likely therapeutic role as an adjunctive and potential utility in prodromal Alzheimers disease.

Datamonitor forecasts that the current late-stage pipeline will yield three blockbusters, but this is by no means guaranteed considering the high risk of failure in Phase III Alzheimers disease trials. Of the pipeline drugs, Datamonitor believes that bapineuzumab and solanezumab have the most commercial and clinical potential.

Datamonitor expects the symptomatic market will remain active in this disease. New symptomatic entrants to the market will include Aricept patch and the first-in-class 5-HT6 receptor antagonist SB-742457.

Your key questions answered

Who will be the winners and losers in the future Alzheimers disease market?

What are the commercial prospects of potentially disease-modifying therapies in Alzheimers disease patients over the next 10 years?

Is the market still receptive to drugs with a purely symptomatic mode of action, in light of the impending availability of generic donepezil?

How will biomarker tests and novel therapeutics affect the way Alzheimers disease is treated? How can this be exploited by drug developers?

For some-more information, Great fully visit:

http://www.aarkstore.com/reports/Pipeline-and-Commercial-Insight-Alzheimers-Disease-Market-cautiously-awaits-the-first-generation-of-disease-modifying-therapies-80667.html

by: Aarkstore Enterprise

POST COMMENT

Walking In A Winter Wonderland: European Christmasmarkets Pipeline And Commercial Insight: Schizophrenia - Opportunity Remains Beyond Positive Symptoms Fat Loss System To Reduce Body Fat Plus Reduce Medical Problems Vitamin E Benefit For Healthy Body Fetal Alcohol Syndrome Symptoms Health Advantages Of Vitamins And Minerals Importance Of Vitamins In Our Body Best Vitamins For Our Body Duraflex Body Kits - Get That Special Look Determining How Much Sleep is Enough for You Best Hemorrhoid Treatment Healthcare Claims Processing – Assuring Accuracy & Profitability Pregnant? baby due in winter,emergency birth, giving birth during a blizzard